Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis

Abdullah S. Al Saleh, Alissa Visram, Harsh Parmar, Eli Muchtar, Francis K. Buadi, Angela Dispenzieri, Rahma Warsame, Martha Q. Lacy, David Dingli, Nelson Leung, Ronald S. Go, Wilson I. Gonsalves, Taxiarchis V. Kourelis, Suzanne R. Hayman, Prashant Kapoor, Morie A. Gertz, Robert A. Kyle, S. Vincent Rajkumar, Shaji K. Kumar

Research output: Contribution to journalArticlepeer-review


This is a retrospective study of patients with multiple myeloma (MM) who were >75 years old. We identified 394 patients and for non-trial patients (n = 350), immunomodulatory drug (IMiD)+dex (32%) was the most commonly used regimen followed by alkylator with steroids or other therapy (21%), alkylator + proteasome inhibitor (PI)+steroid (18%), and IMiD + PI + dex (13%). Overall, achieving ≥ very good partial response was more in patients receiving a triplet compared to other therapies (46% vs. 21%, p < 0.0001). Also, the median overall survival (OS) was significantly longer in patients who were treated with a triplet (median OS: 50.2 vs. 32.8 months, p = 0.0006). In a multivariate for OS, receiving a triplet (HR: 0.65, p = 0.02), not having an R-ISS stage 3 (HR: 0.36, p = 0.0003), and bone marrow plasma cell percentage <60% (HR: 0.69, p = 0.03) were predictive. In conclusion, being able to receive triplet therapy was associated with better survival in our MM patients >75 years old.

Original languageEnglish (US)
Pages (from-to)3011-3018
Number of pages8
JournalLeukemia and Lymphoma
Issue number12
StatePublished - 2021


  • Multiple myeloma
  • elderly
  • outcomes
  • treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis'. Together they form a unique fingerprint.

Cite this